Filippo Alongi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5539688/publications.pdf

Version: 2024-02-01

207	4,886	117453	143772
papers	citations	34 h-index	57 g-index

210	210	210	4710
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. Journal of Clinical Pathology, 2022, 75, 39-44.	1.0	7
2	Reply to: Stereotactic radiotherapy needs more evidence before it can be used routinely to treat metastases: a comment on the paper by Nicosia et al. Radiotherapy and Oncology, 2022, , .	0.3	0
3	[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 273-282.	2.6	37
4	Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy. Radiologia Medica, 2022, , 1.	4.7	3
5	PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. Clinical and Experimental Metastasis, 2022, 39, 443.	1.7	4
6	A novel treatment for malignant spasticity: The therapeutic use of stereotactic radiosurgery (SRS). Radiotherapy and Oncology, 2022, 169, 86-89.	0.3	0
7	1.5T MR-Guided Daily Adaptive Stereotactic Body Radiotherapy for Prostate Re-Irradiation: A Preliminary Report of Toxicity and Clinical Outcomes. Frontiers in Oncology, 2022, 12, 858740.	1.3	11
8	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	1.1	3
9	RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment. Cancers, 2022, 14, 2273.	1.7	1
10	First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. Technical Innovations and Patient Support in Radiation Oncology, 2022, 22, 50-54.	0.6	7
11	Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia. European Heart Journal Supplements, 2022, 24, C248-C253.	0.0	7
12	Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?. Tumori, 2021, 107, 030089162092942.	0.6	3
13	Stereotactic Ablative radiation therapy (SABR) for cardiac arrhythmia: A new therapeutic option?. Radiologia Medica, 2021, 126, 155-162.	4.7	15
14	Radiotherapy activities and technological equipment in Veneto, Italy: a report from the Rete Radioterapica Veneta. Radiologia Medica, 2021, 126, 623-629.	4.7	3
15	Reply to: The course of lung oligometastatic colorectal cancer may be aÂreflection of selection for treatment rather than an effect of stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2021, 197, 76-78.	1.0	2
16	Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. British Journal of Radiology, 2021, 94, 20200848.	1.0	28
17	Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta OncolÃ³gica, 2021, 60, 215-221.	0.8	31
18	PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients. Radiologia Medica, 2021, 126, 460-465.	4.7	8

#	Article	IF	Citations
19	Honey Against Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. An Umbrella Review of Systematic Reviews and Meta- Analyses of the Literature. Reviews on Recent Clinical Trials, 2021, 15, 360-369.	0.4	0
20	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The â€œImpACT-COVID-19 for Patientsâ€•Multi-Centre Observational Study. International Journal of Environmental Research and Public Health, 2021, 18, 340.	1.2	14
21	In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy. Radiotherapy and Oncology, 2021, 155, e20-e21.	0.3	3
22	Current status and recent advances in reirradiation of glioblastoma. Radiation Oncology, 2021, 16, 36.	1.2	80
23	The role of radiotherapy in patients with solid tumours after solid organ transplantation: a systematic review. Lancet Oncology, The, 2021, 22, e93-e104.	5.1	4
24	Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. Future Oncology, 2021, 17, 807-815.	1.1	1
25	Metastasis Directed Therapy and/or Systemic Therapy in Hormone-naive Oligometastatic Prostate Cancer Patient: an Emerging Dilemma. Journal of Medical & Radiation Oncology, 2021, 1, 139-144.	0.0	0
26	OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO. Medical Oncology, 2021, 38, 48.	1.2	4
27	Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5ÂT MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes. Radiologia Medica, 2021, 126, 989-997.	4.7	19
28	MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. Cancers, 2021, 13, 1791.	1.7	21
29	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	1.2	6
30	Radiation-Induced Oral Mucositis in Head and Neck Cancer Patients. Five Years Literature Review. Reviews on Recent Clinical Trials, 2021, 16, 151-165.	0.4	1
31	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 391-396.	0.7	2
32	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiotherapy and Oncology, 2021, 159, 146-154.	0.3	37
33	Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3269-3277.	1.2	15
34	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treatment Reviews, 2021, 98, 102206.	3.4	30
35	Cutaneous soft tissue sarcomas: survival-related factors. Archives of Dermatological Research, 2021, , 1.	1.1	4
36	Salvage local treatment for localized radio-recurrent prostate cancer: a narrative review and future perspectives. Future Oncology, 2021, 17, 4207-4219.	1.1	0

#	Article	IF	Citations
37	The Impact of Different Timing Schedules on Prostate HDR-Mono-Brachytherapy. A TCP Modeling Investigation. Cancers, 2021, 13, 4899.	1.7	2
38	The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. Clinical Lung Cancer, 2021, 22, e767-e773.	1.1	8
39	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. Radiotherapy and Oncology, 2021, 164, 104-114.	0.3	10
40	Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5â€‰T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer. British Journal of Radiology, 2021, 94, 20210521.	1.0	3
41	Reduction of inter-observer differences in the delineation of the target in spinal metastases SBRT using an automatic contouring dedicated system. Radiation Oncology, 2021, 16, 197.	1.2	6
42	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: aÂmulti-institutional analysis. Strahlentherapie Und Onkologie, 2020, 196, 213-221.	1.0	29
43	Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArcâ„¢) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis. Clinical and Experimental Metastasis, 2020, 37, 77-83.	1.7	22
44	Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088). Trials, 2020, 21, 678.	0.7	2
45	Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5â€‰T MR-guided stereotactic body radiotherapy. Radiation Oncology, 2020, 15, 178.	1.2	30
46	Initial Experience With Single-Isocenter Radiosurgery to Target Multiple Brain Metastases Using an Automated Treatment Planning Software: Clinical Outcomes and Optimal Target Volume Margins Strategy. Advances in Radiation Oncology, 2020, 5, 856-864.	0.6	18
47	Two months of radiation oncology in the heart of Italian â€œred zoneâ€•during COVID-19 pandemic: paving a safe path over thin ice. Radiation Oncology, 2020, 15, 191.	1.2	9
48	Adaptive SBRT by 1.5ÂT MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time. Physica Medica, 2020, 80, 34-41.	0.4	19
49	Prostate re-irradiation: current concerns and future perspectives. Expert Review of Anticancer Therapy, 2020, 20, 947-956.	1.1	11
50	Reply to Ghaffari et al. â€œIn regard to Cuccia et al.: impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5â€‰T MR-guided stereotactic body radiotherapy.â€• Radiation Oncology, 2020, 15, 213.	1.2	5
51	Intra-fraction and Inter-fraction analysis of a dedicated immobilization device for intracranial radiation treatment. Radiation Oncology, 2020, 15, 200.	1.2	5
52	A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Scientific Reports, 2020, 10, 13589.	1.6	27
53	Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study. Biomedicines, 2020, 8, 609.	1.4	6
54	Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel. ESMO Open, 2020, 5, e000696.	2.0	0

#	Article	IF	Citations
55	Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. Lancet Oncology, The, 2020, 21, 759-760.	5.1	34
56	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiation Oncology, 2020, 15, 92.	1.2	31
57	In reply to Simcock et al.. Clinical and Translational Radiation Oncology, 2020, 23, 65.	0.9	1
58	Linac-based SBRT as aÂfeasible salvage option for local recurrences in previously irradiated prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 628-636.	1.0	15
59	Feasibility and safety of 1.5ÂT MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2379-2397.	1.2	25
60	Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 813-820.	1.0	22
61	PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Journal of Cancer Research and Clinical Oncology, 2020, 146, 2311-2317.	1.2	9
62	Standard (8 weeks) vs long (12 weeks) Timing to Minimally-Invasive Surgery after NeoAdjuvant Chemoradiotherapy for Rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). European Journal of Surgical Oncology, 2020, 46, e89-e90.	0.5	0
63	1.5â€‰T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiation Oncology, 2020, 15, 69.	1.2	94
64	What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?. Lung Cancer, 2020, 146, 263-275.	0.9	4
65	Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiologia Medica, 2020, 125, 491-499.	4.7	8
66	Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2351-2358.	1.2	21
67	A comparative analysis between radiation dose intensification and conventional fractionation in neoadjuvant locally advanced rectal cancer: a monocentric prospective observational study. Radiologia Medica, 2020, 125, 990-998.	4.7	28
68	Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Review of Anticancer Therapy, 2020, 20, 387-402.	1.1	24
69	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.3	9
70	Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?. Oncoscience, 2020, 7, 19-20.	0.9	5
71	Benign Intracranial Lesions - Radiotherapy: An Overview of Treatment Options, Indications and Therapeutic Results. Reviews on Recent Clinical Trials, 2020, 15, 93-121.	0.4	2
72	The role of postoperative radiotherapy for thymomas: a multicentric retrospective evaluation from three Italian centers and review of the literature. Journal of Thoracic Disease, 2020, 12, 7518-7530.	0.6	9

#	Article	IF	Citations
73	Impact of radiation therapy on pain relief of cancer patients affected by on malignant psoas syndrome: 26 years of experience. Indian Journal of Palliative Care, 2020, 26, 348.	1.0	9
74	A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). Radiotherapy and Oncology, 2019, 131, 208-214.	0.3	9
75	Dose variability in different lymph node levels during locoregional breast cancer irradiation: the impact of deep-inspiration breath hold. Strahlentherapie Und Onkologie, 2019, 195, 13-20.	1.0	20
76	PhaseÂII study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. Strahlentherapie Und Onkologie, 2019, 195, 113-120.	1.0	32
77	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori, 2019, 105, 516-523.	0.6	8
78	Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiotherapy and Oncology, 2019, 139, 83-86.	0.3	40
79	Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2547-2554.	1.2	26
80	Impact of surface-guided positioning on the use of portal imaging and initial set-up duration in breast cancer patients. Strahlentherapie Und Onkologie, 2019, 195, 964-971.	1.0	13
81	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. European Urology, 2019, 76, 732-739.	0.9	99
82	Deep inspiration breath-hold intensity modulated radiation therapy in a large clinical series of 239 left-sided breast cancer patients: a dosimetric analysis of organs at risk doses and clinical feasibility from a single center experience. British Journal of Radiology, 2019, 92, 20190150.	1.0	13
83	Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma. Lancet Oncology, The, 2019, 20, e611.	5.1	0
84	Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system. Radiation Oncology, 2019, 14, 184.	1.2	17
85	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. British Journal of Radiology, 2019, 92, 20181026.	1.0	4
86	Stereotactic body radiotherapy of central lung malignancies using aÂsimultaneous integrated protection approach. Strahlentherapie Und Onkologie, 2019, 195, 719-724.	1.0	14
87	Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases. Cancers, 2019, 11, 160.	1.7	68
88	Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. Critical Reviews in Oncology/Hematology, 2019, 141, 102-111.	2.0	31
89	The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, e501-e510.	1.1	11
90	Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases. Frontiers in Oncology, 2019, 9, 206.	1.3	28

#	Article	IF	Citations
91	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	1.2	69
92	Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2019, 138, 24-28.	2.0	32
93	Modern radiotherapy in cancer treatment during pregnancy. Critical Reviews in Oncology/Hematology, 2019, 136, 13-19.	2.0	33
94	New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?. Translational Andrology and Urology, 2019, 8, S538-S541.	0.6	19
95	Standard (8â€‰weeks) vs long (12â€‰weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). BMC Cancer, 2019, 19, 1215.	1.1	10
96	Linac-based radiosurgery for multiple brain metastases: Comparison between two mono-isocenter techniques with multiple non-coplanar arcs. Radiotherapy and Oncology, 2019, 132, 70-78.	0.3	40
97	Combination of novel systemic agents and radiotherapy for solid tumors â€“ Part II: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Over Reviews in Oncology/Hematology, 2019, 134, 104-119.	2.0	10
98	Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. Radiologia Medica, 2019, 124, 309-314.	4.7	23
99	Linac-based radiosurgery or fractionated stereotactic radiotherapy with flattening filter-free volumetric modulated arc therapy in elderly patients. Strahlentherapie Und Onkologie, 2019, 195, 218-225.	1.0	27
100	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. Clinical Genitourinary Cancer, 2019, 17, e187-e194.	0.9	14
101	Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey. Radiologia Medica, 2019, 124, 211-217.	4.7	5
102	Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)â€”Lung Working Group. Radiologia Medica, 2019, 124, 136-144.	4.7	8
103	Combination of novel systemic agents and radiotherapy for solid tumors â€“ part I: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Over Reviews in Oncology/Hematology, 2019, 134, 87-103.	2.0	7
104	Using Imaging to Design Dose Volume Constraints for Target and Normal Tissue to Reduce Toxicity. , 2019, , 75-83.		0
105	Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience. Radiologia Medica, 2018, 123, 406-414.	4.7	17
106	An update on radiation therapy in head and neck cancers. Expert Review of Anticancer Therapy, 2018, 18, 359-364.	1.1	21
107	Stereotactic body radiotherapy for lung oligometastases: Literature review according to PICO criteria. Tumori, 2018, 104, 148-156.	0.6	14
108	Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. Radiologia Medica, 2018, 123, 719-725.	4.7	22

#	Article	IF	Citations
109	Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy. International Journal of Cardiology, 2018, 255, 175-183.	0.8	57
110	Linac-based VMAT radiosurgery for multiple brain lesions: comparison between a conventional multi-isocenter approach and a new dedicated mono-isocenter technique. Radiation Oncology, 2018, 13, 38.	1.2	117
111	Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. Aging Clinical and Experimental Research, 2018, 30, 533-538.	1.4	18
112	Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study. Physica Medica, 2018, 49, 135-138.	0.4	8
113	Reply to â€˜Comment on â€˜Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric studyâ€™â€™. British Journal of Cancer, 2018, 118, e2-e2.	2.9	0
114	Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: No Way Out Without a Randomized Trial?. Journal of Clinical Oncology, 2018, 36, 2558-2559.	0.8	3
115	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. Radiation Oncology, 2018, 13, 166.	1.2	27
116	Daily IGRT for prostate cancer: Can we stop the train?. Radiotherapy and Oncology, 2018, 128, 389-390.	0.3	1
117	Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer. Breast Care, 2018, 13, 285-291.	0.8	16
118	Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Medical Oncology, 2018, 35, 121.	1.2	28
119	Cost-effectiveness of Linac-based single-isocenter non-coplanar technique (HyperArcTM) for brain metastases radiosurgery. Clinical and Experimental Metastasis, 2018, 35, 601-603.	1.7	8
120	Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. In Vivo, 2018, 32, 159-164.	0.6	14
121	Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37â€“43. European Urology, 2017, 71, e121-e122.	0.9	0
122	Consolidative local therapy in oligometastatic patients. Lancet Oncology, The, 2017, 18, e60.	5.1	4
123	Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis. Physica Medica, 2017, 44, 188-195.	0.4	29
124	Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost. Radiologia Medica, 2017, 122, 464-471.	4.7	30
125	Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18 FDG-PET/CT. Journal of Thoracic Oncology, 2017, 12, 547-555.	0.5	16
126	Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): AÂMono-institutional Report on Feasibility and Acute Toxicity. Clinical Genitourinary Cancer, 2017, 15, e667-e673.	0.9	35

#	Article	IF	Citations
127	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. British Journal of Cancer, 2017, 116, 1520-1525.	2.9	121
128	Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. Radiologia Medica, 2017, 122, 676-682.	4.7	17
129	Stereotactic precision and conventional radiotherapy evaluation (SPACE)-Trial for medically inoperable Stage I NSCLC: A lost opportunity?. Radiotherapy and Oncology, 2017, 122, 319.	0.3	0
130	18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. Radiologia Medica, 2017, 122, 952-959.	4.7	16
131	Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. Critical Reviews in Oncology/Hematology, 2017, 117, 48-56.	2.0	12
132	Induction chemotherapy for nasopharyngeal cancer: AnÂeternally unfinished issue?. European Journal of Cancer, 2017, 82, 153-154.	1.3	0
133	Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncology, The, 2017, 18, e379-e393.	5.1	15
134	Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results. Technology in Cancer Research and Treatment, 2017, 16, 310-315.	0.8	32
135	Three-dimensional conformal versus intensity modulated radiotherapy in breast cancer treatment: is necessary a medical reversal?. Radiologia Medica, 2017, 122, 146-153.	4.7	19
136	Simultaneous Integrated Bilateral Breast and Nodal Irradiation with Volumetric arc Therapy: Case Report and Literature Review. Tumori, 2016, 102, S32-S34.	0.6	6
137	Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. Journal of Clinical Oncology, 2016, 34, 2940-2941.	0.8	5
138	Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy. Critical Reviews in Oncology/Hematology, 2016, 103, 49-61.	2.0	26
139	In Regard to Boero etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 95, 855-856.	0.4	2
140	Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach. Expert Review of Anticancer Therapy, 2016, 16, 731-740.	1.1	27
141	Watch-and-wait versus surgical resection for patients with rectal cancer. Lancet Oncology, The, 2016, 17, e133-e134.	5.1	1
142	A Plethora of Therapeutic Opportunities for Elderly Patients With Cancer: A Nontrivial Choice. Journal of Clinical Oncology, 2016, 34, 1963-1964.	0.8	2
143	SBRT for prostate cancer: Challenges and features from a physicist prospective. Physica Medica, 2016, 32, 479-484.	0.4	23
144	In Regard to Kubicek etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1318-1319.	0.4	1

#	Article	IF	Citations
145	Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treatment Reviews, 2016, 50, 48-60.	3.4	40
146	Low-Dose Bath with Volumetric Modulated arc Therapy in Breast Cancer: â€œMuch ado about Nothing?â€. Tumori, 2016, 102, 335-336.	0.6	8
147	Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. British Journal of Radiology, 2016, 89, 20160146.	1.0	15
148	Spinal metastases: Is stereotactic body radiation therapy supported by evidences?. Critical Reviews in Oncology/Hematology, 2016, 98, 147-158.	2.0	37
149	The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project. Technology in Cancer Research and Treatment, 2016, 15, 365-376.	0.8	6
150	Radiotherapy in patients with connective tissue diseases. Lancet Oncology, The, 2016, 17, e109-e117.	5.1	42
151	Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for brain metastases: a dosimetric volumetric-modulated arc therapy study. Radiologia Medica, 2016, 121, 60-69.	4.7	25
152	Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A doseâ€“volume analysis. Head and Neck, 2016, 38, E815-9.	0.9	26
153	Multimodality imaging for early assessment of head and neck patients during induction chemotherapy: a reliable future option?. Translational Cancer Research, 2016, 5, S405-S407.	0.4	0
154	18F-Sodium Fluoride PETâ€“CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, e67-e68.	0.5	6
155	Letter. Neurosurgery, 2015, 77, E310.	0.6	9
156	Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy. Clinical Nuclear Medicine, 2015, 40, e496-e500.	0.7	30
157	Personalizedâ€”Not Omittedâ€”Radiation Oncology for Breast Cancer. Journal of Clinical Oncology, 2015, 33, 4313-4314.	0.8	14
158	Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. Critical Reviews in Oncology/Hematology, 2015, 94, 360-370.	2.0	23
159	Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. Cancer Treatment Reviews, 2015, 41, 511-518.	3.4	31
160	Dosimetrics of intracranial stereotactic radiosurgery. Strahlentherapie Und Onkologie, 2015, 191, 810-811.	1.0	9
161	Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. British Journal of Radiology, 2015, 88, 20140736.	1.0	38
162	In Regard to Chung etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 941-942.	0.4	0

#	Article	IF	Citations
163	SBRT and extreme hypofractionation: A new era in prostate cancer treatments?. Reports of Practical Oncology and Radiotherapy, 2015, 20, 411-416.	0.3	12
164	Solitary Brain Metastasis from Non-Small Cell Lung Cancer. , 2014, , 131-139.		0
165	What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?. Acta OncolÃ³gica, 2014, 53, 990-992.	0.8	11
166	Toxicity of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: A Potential Comparison Bias. Journal of Clinical Oncology, 2014, 32, 3454-3454.	0.8	8
167	From radiobiology to technology: what is changing in radiotherapy for prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 553-564.	1.1	28
168	Salvage therapy of small volume prostate cancer nodal failures: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 24-35.	2.0	25
169	Choline-PET in prostate cancer management: The point of view of the radiation oncologist. Critical Reviews in Oncology/Hematology, 2014, 91, 234-247.	2.0	32
170	Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiation Oncology, 2014, 9, 91.	1.2	81
171	Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1795-1800.	1.2	20
172	Stereotactic radiosurgery for patients with brain metastases. Lancet Oncology, The, 2014, 15, e246-e247.	5.1	12
173	Could Single-high-dose Radiotherapy be Considered the New Frontier of Stereotactic Ablative Radiation Therapy?. Tumori, 2014, 100, e92-e93.	0.6	3
174	Postoperative Breast Radiotherapy after Neoadjuvant Chemotherapy: Which Uncertainties still Remain?. Tumori, 2014, 100, e212-e213.	0.6	6
175	The Role of Stereotactic Ablative Radiotherapy in Oncological and Non-Oncological Clinical Settings: Highlights from the 7th Meeting of AIRO â€“ Young Members Working Group (AIRO Giovani). Tumori, 2014, 100, e214-e229.	0.6	12
176	Could single-high-dose radiotherapy be considered the new frontier of stereotactic ablative radiation therapy?. Tumori, 2014, 100, e92-3.	0.6	2
177	Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case. Radiation Oncology, 2013, 8, 176.	1.2	27
178	Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiation Oncology, 2013, 8, 171.	1.2	98
179	SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiation Oncology, 2013, 8, 148.	1.2	91
180	The â€œPROCAINA (PROstate CAncer INdication Attitudes) Projectâ€•(Part II) â€” A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiologia Medica, 2013, 118, 1220-1239.	4.7	17

#	Article	IF	Citations
181	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 550-563.	2.0	52
182	The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists. Medical Oncology, 2013, 30, 729.	1.2	15
183	Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy. Acta OncolÃ³gica, 2013, 52, 545-552.	0.8	32
184	Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiotherapy and Oncology, 2013, 107, 414-418.	0.3	141
185	Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2013, 86, 336-342.	0.4	168
186	The â€œBUONGIORNOâ€•Project: Burnout Syndrome Among Young Italian Radiation Oncologists. Cancer Investigation, 2013, 31, 522-528.	0.6	41
187	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori, 2013, 99, 637-649.	0.6	18
188	Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. Anticancer Research, 2013, 33, 4537-43.	0.5	22
189	Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. Oncologist, 2012, 17, 1100-1107.	1.9	185
190	Can volumetric modulated arc therapy with flattening filter free beams play a role in stereotactic body radiotherapy for liver lesions? A volume-based analysis. Medical Physics, 2012, 39, 1112-1118.	1.6	49
191	Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique. Journal of Applied Clinical Medical Physics, 2012, 13, 138-147.	0.8	26
192	Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Critical Reviews in Oncology/Hematology, 2012, 84, 101-108.	2.0	44
193	A strategy for young members within national radiation oncology societies: the Italian experience (AIRO Giovani group). Reports of Practical Oncology and Radiotherapy, 2012, 17, 259-261.	0.3	11
194	Initial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma. Reports of Practical Oncology and Radiotherapy, 2012, 17, 262-268.	0.3	13
195	Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. Acta OncolÃ³gica, 2012, 51, 618-623.	0.8	76
196	Relationship Between Molecular Oncology and Radiotherapy in Malignant Gliomas (An Overview). , 2012, , 103-110.		0
197	Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiation Oncology, 2012, 7, 204.	1.2	38
198	Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. Radiation Oncology, 2012, 7, 145.	1.2	72

#	Article	IF	Citations
199	Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations. Radiation Oncology, 2012, 7, 16.	1.2	57
200	Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiation Oncology, 2011, 6, 113.	1.2	107
201	In Response to Dr. Russi and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1279-1280.	0.4	0
202	Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: Feasibility and clinical preliminary results. Acta OncolÃ³gica, 2011, 50, 528-538.	0.8	51
203	Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients. Radiation Oncology, 2010, 5, 93.	1.2	35
204	Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. Radiation Oncology, 2010, 5, 94.	1.2	34
205	IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiotherapy and Oncology, 2009, 93, 207-212.	0.3	126
206	Remission of Refractory Neurosarcoidosis Treated With Brain Radiotherapy. Neurologist, 2008, 14, 120-124.	0.4	20
207	Significant reduction of acute toxicity following pelvic irradiation with Helical Tomotherapy in patients with localized prostate cancer. Radiotherapy and Oncology, 2007, 84, 164-170.	0.3	84